Stock Option Plan - The stock option plan allows the company to grant rights to subscribe for up to 15,954,685 shares, representing approximately 9.30% of the issued shares as of the date of the 2024 annual report[3]. - As of June 30, 2024, a total of 8,958,290 stock options have lapsed, with no options granted, exercised, or cancelled during the fiscal year ending June 30, 2024[3]. - The number of stock options available for grant under the plan as of July 1, 2023, and June 30, 2024, is 6,996,395 and 15,954,685, respectively[3]. - The stock option plan is effective for a period of 10 years from the adoption date, unless otherwise cancelled or amended[3]. - No stock options were granted to connected persons or service providers that exceeded 0.1% of the relevant class of issued shares during any 12-month period as of July 1, 2023, and June 30, 2024[5]. - Any stock options granted must be approved by shareholders at a general meeting[4]. - The total value of stock options granted to connected persons must not exceed HKD 5,000,000 based on the closing price of shares on the grant date[4]. - The company emphasizes the importance of shareholder approval for any stock option grants to ensure compliance with listing rules[4]. Governance and Oversight - The company’s board of directors includes executive and independent non-executive directors, ensuring governance and oversight[7]. - The information in this announcement does not affect other data contained in the 2024 annual report[6].

Core Viewpoint - Wei Jun Biotechnology (00660.HK) reported a revenue of approximately HKD 377 million for the fiscal year ending June 30, 2025, representing an increase of about 1.9% compared to the previous year. The company also improved its net loss to approximately HKD 14.6 million from HKD 44.2 million in the prior year, primarily due to a significant reduction in impairment losses on non-financial assets [1]. Financial Performance - The group's revenue and gross profit remained relatively stable compared to the previous year, with a reported revenue of approximately HKD 377 million [1]. - The net loss for the fiscal year ending June 30, 2025, was approximately HKD 14.6 million, a significant improvement from the net loss of approximately HKD 44.2 million for the fiscal year ending June 30, 2024 [1]. - The improvement in net loss was mainly attributed to a substantial decrease in impairment losses on non-financial assets during the reporting period [1]. Strategic Outlook - The company plans to continue pursuing strategic acquisitions to capture new business opportunities in the Chinese market, aiming to further strengthen its revenue and profit base [1]. - The company is actively seeking projects with growth potential for acquisition or investment and is in discussions with various parties regarding such opportunities [1].

Financial Performance - The total revenue for the year ended June 30, 2025, was HKD 377,168,000, representing a 1% increase from HKD 370,069,000 in the previous year[2] - Gross profit for the same period was HKD 36,004,000, up from HKD 34,181,000, indicating a growth of 5%[2] - The net loss for the year was HKD 10,701,000, a significant improvement compared to a net loss of HKD 65,707,000 in the prior year, reflecting a reduction of approximately 84%[2] - The company's basic and diluted loss per share improved to HKD (8.43) from HKD (25.78) year-over-year[2] - The group reported a net loss of approximately HKD 14,623,000 for the year ending June 30, 2025, compared to a net loss of approximately HKD 44,212,000 for the previous year, indicating an improvement in financial performance[32] - The company reported a loss attributable to owners of approximately HKD 14.6 million for the year ending June 30, 2025, an improvement from a loss of HKD 44.2 million in the previous year[48] Assets and Liabilities - Total assets as of June 30, 2025, amounted to HKD 214,655,000, compared to HKD 209,498,000 in the previous year, showing a slight increase[4] - Current liabilities increased to HKD 277,308,000 from HKD 253,847,000, indicating a rise of approximately 9%[5] - The total accounts receivable amounted to HKD 31,908,000 as of June 30, 2025, down from HKD 34,945,000 in the previous year, with a net accounts receivable of HKD 28,787,000 after deducting provisions for losses[34] - As of June 30, 2025, the group's total liabilities were approximately HKD 178.0 million, an increase from HKD 135.9 million the previous year[51] - The net current liabilities were approximately HKD 170.5 million, compared to HKD 139.4 million as of June 30, 2024[51] - The company’s net debt to total assets ratio was approximately 79.9%, up from 63.8% the previous year[51] Cash Flow and Financial Stability - The company's cash and cash equivalents rose to HKD 6,558,000 from HKD 2,161,000, marking a significant increase of 204%[4] - The group recognized a foreign exchange gain of HKD 1,000 from overseas operations, contrasting with a loss of HKD 72 in the previous year[3] - The board believes that the group will have sufficient cash resources to meet its operational and financing needs within the next twelve months from the announcement date, thus justifying the preparation of financial statements on a going concern basis[10] - The group had a total of approximately HKD 20.3 million in assets pledged as collateral for bank borrowings as of June 30, 2025[54] - The company has implemented measures to ensure financial stability, including obtaining loans from the ultimate holding company and closely monitoring administrative expenses[56] Operational Highlights - The group plans to pursue strategic acquisitions to capture new business opportunities in the mainland China market and strengthen its revenue and profitability fundamentals[12] - The group is actively negotiating with potential investors to raise sufficient funds through financing arrangements[11] - The group has reduced its workforce to 61 employees as of June 30, 2025, down from 140 employees the previous year[57] - No significant acquisitions or disposals of subsidiaries occurred during the year ending June 30, 2025[58] - The company has not engaged in any purchase, sale, or redemption of its listed securities during the year ending June 30, 2025[59] Expenses and Costs - Sales expenses increased by approximately 13.3%, rising from HKD 12.4 million to HKD 14.1 million[45] - Administrative expenses slightly increased by about 2.6%, from HKD 20.3 million to HKD 20.8 million[46] - The group’s research and development expenses were HKD 1,610,000 for the year ending June 30, 2025, compared to HKD 2,719,000 in the previous year, indicating a reduction in R&D investment[31] - The group recognized an impairment loss of approximately HKD 1.7 million for non-current assets, significantly reduced from HKD 58.1 million in the previous year[47] Governance and Reporting - The board has resolved not to recommend the payment of a final dividend for the year ending June 30, 2025[55] - The company has adopted the corporate governance code as per the listing rules, with some deviations noted[61] - The audit committee has reviewed the annual results for the year ending June 30, 2025, in conjunction with the external auditor[66] - The company will publish its annual report containing all information required by listing rules at an appropriate time[68] - The board expresses gratitude to all employees and management for their contributions during the year[69] - The board members include executive director Lin Jia Jun (Chairman and CEO) and independent non-executive directors Huang Bao Qiang, Wang Zi Niu, and Xu Hui Ling[70]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 瑋俊生物科技有限公司 Wai Chun Bio-Technology Limited （於開曼群島註冊成立之有限公司） （股份代號：660） (i)有關建議股本重組以及 建議更改現有可換股債券條款之關連交易經修訂預期時間表； 及 (ii)延長認購協議之最後截止日期 股本重組之更新資料及經修訂預期時間表 茲 提 述 瑋 俊 生 物 科 技 有 限 公 司（「本公司」）日 期 為 二 零 二 五 年 三 月 二 十 八 日 之 通 函（「通函一」），以 及 本 公 司 日 期 為 二 零 二 五 年 四 月 二 十 三 日、二 零 二 五 年 五 月 二 十一日、二零二五年八月二十一日及二零二五年九月十一日的公告（「該等公告」）。 除 另 有 界 定 或 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 通 函 一 及 該 等 公 告 所 界 定 者 具有相同涵義。 誠 如 該 通 函 與 該 等 ...

玮俊生物科技(00660)发布公告，集团预期于截至2025年6月30日止年度取得的净亏损不超过1300万港 元，亏损相比截至2024年6月30日止年度的净亏损约6570万港元大幅减少。亏损大幅减少的主要原因为 报告年度内非金融资产减值亏损减少。 ...

智通财经APP讯，玮俊生物科技(00660)发布公告，集团预期于截至2025年6月30日止年度取得的净亏损 不超过1300万港元，亏损相比截至2024年6月30日止年度的净亏损约6570万港元大幅减少。亏损大幅减 少的主要原因为报告年度内非金融资产减值亏损减少。 ...

Group 1 - The company expects to record a net loss of no more than HKD 13 million for the fiscal year ending June 30, 2025, which represents a significant reduction compared to a net loss of approximately HKD 65.7 million for the fiscal year ending June 30, 2024 [1] - The substantial decrease in loss is primarily attributed to a reduction in impairment losses on non-financial assets during the reporting year [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負 責，對其準確性及完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 瑋俊生物科技有限公司 Wai Chun Bio-Technology Limited （於開曼群島註冊成立之有限公司） （股份代號：660） – 1 – 股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 瑋俊生物科技有限公司 主席兼行政總裁 林家俊 香港，二零二五年九月二十六日 盈利預告 – 虧損顯著減少 本 公 告 乃 瑋 俊 生 物 科 技 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）根 據香港聯合交易所有限公司證券上市規則第13.09(2)(a)條（「上市規則」）及《證 券 及 期貨條例》（香港法例第571章）第XIVA部的內幕消息條文（定義見上市規則）而刊發。 本 公 司 董 事 會（「董事會」）謹 此 通 知 本 公 司 股 東（「股 東」）及 潛 在 投 資 者，根 據 對 本 集 團 截 至 二 零 二 五 年 六 月 三 十 日 止 年 度 未 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 瑋俊生物科技有限公司 Wai Chun Bio-Technology Limited （於開曼群島註冊成立之有限公司） （股份代號：660） 承董事會命 瑋俊生物科技有限公司 主席兼行政總裁 林家俊 香港，二零二五年九月十八日 於 本 公 告 日 期，董 事 會 包 括 一 名 執 行 董 事，為 林 家 俊 先 生（主 席 及 行 政 總 裁），及 三名獨立非執行董事，分別為王子牛先生、許慧齡女士和黃保強先生。 董事會會議通知 瑋 俊 生 物 科 技 有 限 公 司（「本公司」）之 董 事（「董 事」）會（「董事會」）謹 此 宣 佈，本 公 司 將 於 二 零 二 五 年 九 月 三 十 日（星 期 二）假 座 香 港 灣 仔 港 灣 道26號華潤大廈40樓 4001–02室 舉 行 董 事 會 會 議，藉 以 考 慮 及 批 准（其 中 包 括）本 公 司 及 其 附 屬 公 司 截 至 二 零 二 ...

於 股 東 特 別 大 會 上，該 通 函 所 載 之 提 呈 決 議 案 已 以 投 票 方 式 進 行 表 決。本 公 司 之香港股份過戶登記處聯合證券登記有限公司獲委聘在股東特別大會上擔任點 票工作之監票人。 中 國 成 功 有 限 公 司（「中國成功」）及 林 清 渠 先 生 分 別 持 有91,550,243股 及72,400股 股 份，合共佔股東特別大會日期已發行股份總數約51.34%，被要求於股東特別大會 上 就 日 期 為 二 零 二 五 年 八 月 二 十 五 日 的 股 東 特 別 大 會 通 告（「通 告」）所 載 唯 一 決 議案放棄投票。 於股東特別大會日期，本公司已發行股份總數為178,476,453股股份，其中賦予股 東（中 國 成 功 及 其 聯 繫 人（包 括 林 清 渠 先 生）除 外）出 席 股 東 特 別 大 會 並 於 會 上 投 票贊成或反對通告所載唯一決議案的股份總數為86,853,810股。出 席 會 議 的 股 東 就唯一決議案投贊成或反對票的股份總數為40,026,517股。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負 責，對其準確 ...